Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 62%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is expected to continue on a positive trajectory due to strong sales of their main product Brukinsa, expansion into new therapeutic areas, and potential for accelerated approval for their other drugs. The company's promising pipeline and positive reception from experts bode well for future revenue growth. Despite a setback in their CELESTIAL-301 trial, analysts remain bullish on BeOne's overall potential in the biotech industry and foresee potential stock price growth in the next year.

Bears say

BeOne Medicines is a commercial-stage biotech firm that produces oncology therapeutics, with their main product, Brukinsa, making up 74% of total revenue. They have two other approved commercialized drugs in their portfolio, but those generate the majority of their revenue from China. The company is also advancing more than 50 drugs in clinical trials. However, there are risks to the investment thesis, including clinical development, competition, regulatory and sector risks. Additionally, their flagship product is on track to generate over $5B in worldwide revenues in 2026, and their Phase 3 trials for various programs have demonstrated positive results. However, there may be concerns about the potential for competitive drugs and the length of the clinical trial process. It will be important to closely monitor the success and progression of their current pipeline and the company's ability to maintain competitive advantages in the market.

BeiGene Ltd (ONC) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 62% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 13 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $405.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $405.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.